With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

Girl rubbing her eyes

Bausch Health Companies Inc. stocks Bausch + Lomb Inc. with the first preservative-free OTC antihistamine eye drops approved in the US ahead of its planned spin-out of the eye health business.

The approval on 25 September of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after the Food and Drug...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation